Bionure is a R&D pharma company, a spin-off from IDIBAPS – the HospitBarcelona and the Spanish National Council CSIC (Spain), developing the neuroprotectant BN201. The company has benefited from a Series A financing led by Alta Life Sciences.
BN201 is a small molecule that has successfully completed a clinical phase 1 study on the safety, tolerability and pharmacokinetics in single and multiple doses in healthy volunteers, under the approval of the MHRA, UK. The neuroprotective activity and the ability of BN201 to induce remyelination of the neuron, as shown in preclinical studies, provide the basis for future research and clinical experiments for the treatment of several diseases in neurology with high unmet needs, including acute optic neuritis (AON, a rare ophthalmological disease) and multiple sclerosis (MS).
Since May 26, 2020, BN201 has been integrated into the portfolio of Accure Therapeutic under the name ACT-01.